Evidence map›Paper›PMID 30591031›Full record

Trial reportBMC nephrology2018

Effect of valerian on cognitive disorders and electroencephalography in hemodialysis patients: a randomized, cross over, double-blind clinical trial.

Afshin Samaei, Monir Nobahar, Zaynab Hydarinia-Naieni, Abbas Ali Ebrahimian, Mohammad Reza Tammadon, Raheb Ghorbani, Abbas Ali Vafaei

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Uremic Toxins, CKD, and Cognitive Dysfunction.Journal of the American Society of Nephrology : JASN · 2025
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Afshin SamaeiResearch Center and Department of Physiology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran.
Monir NobaharNursing Care Research Center and Social Determinants of Health Research Center, Faculty of Nursing and Midwifery, Semnan University of Medical Sciences, Semnan, 3513138111, Iran. Nobahar43@Semums.ac.ir.
Zaynab Hydarinia-NaieniNursing Care Research Center, Semnan University of Medical Sciences, Semnan, Iran.
Abbas Ali EbrahimianDepartment of Nursing, Faculty of Nursing and Midwifery, Semnan University of Medical Sciences, Semnan, Iran.
Mohammad Reza TammadonKowsar Hospital, Semnan University of Medical Sciences, Semnan, Iran.
Raheb GhorbaniSocial Determinants of Health Research Center, Department of Epidemiology and Biostatistics, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran.
Abbas Ali VafaeiRehabilitation Research Center, Neurology Department, Kowsar Hospital, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran.
Semnan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prevalence of cognitive disorders in hemodialysis patients is twice as high as the general population, while these disorders often are undiagnosed. Timely prevention and treatment can improve their personal and social functions. Aim of study was determined the effect of Valerian on cognitive disorders and electroencephalography (EGG) in hemodialysis patients.

methodsThis crossover, double-blind clinical trial was conducted on 39 hemodialysis patients. The patients were randomly divided into two groups. Group A (n = 19) took Valerian capsules and Group B (n = 20) received placebo capsules 60 min before bedtime for one month. The type of treatment was replaced between the two groups after a one-month wash-out. The Mini Mental State Examination (MMSE) questionnaire was completed and EGG was performed before and after intervention in both periods.

resultsThe cognitive scores of the Group valerian were increased significantly in the first (p = 0.003) and the second (p = 0.005) periods. In addition, the mean increase in the cognitive scores in the Group valerian was significant in the first (p = 0.028) and the second periods (p = 0.030). However, the changes in EGG showed no significant difference before and after intervention in two groups.

conclusionThe findings of this study indicated that valerian could be effective and significantly improve patients' cognitive status; however, no significant changes were observed in the electroencephalography of the hemodialysis patients.

trial registrationIRCT201606076318N7 -2016-06-17.

Indexed as

PhytotherapyValerianAdultAgedAged, 80 and overCognition DisordersCross-Over StudiesDouble-Blind MethodElectroencephalographyFemaleHumansMaleMental Status and Dementia TestsMiddle AgedPlant ExtractsRenal DialysisPlant ExtractsCognitive Disorders & ElectroencephalographyHemodialysisValerian

Identifiers

PMID30591031
PMCPMC6309073
OpenAlexW2908212351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.